ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing misleading statements to investors regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company reportedly made confident statements about July 1, 2026 coverage while concealing material adverse facts, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.